Loading...
Loading...
HILS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 1.8M |
| Operating I/L | -1.8M |
| Other Income/Expense | -8,471.6M |
| Interest Income | 0.0M |
| Pretax | -1.8M |
| Income Tax Expense | 1,594.4M |
| Net Income/Loss | -1,596.2M |
Hillstream BioPharma, Inc. is a pre-clinical biotechnology company specializing in developing novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron-mediated cell death (IMCD) for the treatment of resistant cancers. The company's product candidates include HSB-1216, an IMCD inducer targeting solid tumors; HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single-digit nanomolar IC50 against PI3K-delta and HDAC6; and HSB-114, an immunotherapeutic agent using Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.
